Junior Editors of European Pharmaceutical Review, Hannah Balfour and Victoria Rees, discuss some of the most noteworthy news and announcements from this year.
Hannah Balfour
Hannah Balfour
Junior Editor at European Pharmaceutical Review.
This year has been… interesting. While UK residents entered 2020 expecting nothing more significant than Brexit, COVID-19 has knocked us all for six. However, despite the hardships of the pandemic, it is undeniable that the novel coronavirus has pushed pharmaceutical R&D further than ever before, giving the industry a once-in-a-lifetime opportunity to showcase its skills and rebuild its reputation.
In my opinion, the pandemic has brought two key concepts to the fore, without which we would not have the first COVID-19 vaccine approved, if only temporarily, for use. To me, 2020 has been the year of pharma collaboration and innovation – something that has never been seen before.
In the past, pharma companies (and big pharma in particular) have been extremely secretive – and the market intensely competitive. While the latter may never change, the challenges of the pandemic forced a new approach to information sharing. Perhaps the most notable collaboration this year was between Pfizer and BioNTech in the development of their mRNA vaccine candidate, BNT162b2, which has now become the first COVID-19 vaccine in the world to receive Emergency Use Authorisation and is already being administered to residents in the UK. For me, this approval is one of the most important stories we have reported on all year at EPR.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
While some may be suggesting that this will draw a line under COVID, and that the end of the pandemic is in sight, the pharma industry knows there is still so much more to come.
Firstly, given the numerous challenges associated with the distribution and storage of the BNT162b2 vaccine, there is space on the market for other candidates to flourish, such as those that would not require such stringent distribution and storage methods or vaccine candidates that show promise in populations currently not approved to receive BNT162b2, like children under 16 and pregnant women.
Additionally, vaccine production, distribution and administration will take time. With so many needing multiple doses of vaccine, the wait to receive one will be long; and so therapeutics that can help ease the burden of COVID-19 until the population is better protected are still essential.
This brings me on to innovation, which 2020 has been full of – both at home and in the lab. It is worth noting that the BNT162b2 vaccine and many other promising candidates currently under regulatory review are new technologies – never before approved for use in humans. Earlier this year, John Liddell, the Chief Technologist at the UK Centre for Process Innovation (CPI), explained why COVID-19 turned vaccine developers towards new technologies in an article titled ‘Comparison of new vaccine approaches – COVID-19’, published in EPR Issue 3 2020. He cited specificity, safety and speed of response as the primary drivers behind the use of mRNA and virally-vectored vaccines to address the pandemic. For those seeking to understand how innovation has been at the heart of the pharma pandemic response, or to better understand the platforms upon which many COVID-19 vaccines are based, this article is a definite must-read.
Victoria Rees
Victoria Rees
Junior Editor at European Pharmaceutical Review.
We have witnessed a colossal effort from the pharmaceutical industry this year, which quickly mobilised to respond to the COVID-19 pandemic. While this is still ongoing, it is reassuring to see progress being made, with vaccines and therapeutics gaining emergency approvals around the world.
With so much attention being paid to those infected by SARS-CoV-2, many researchers have been investigating the medicines taken by patients before hospitalisation that correlated with a reduced risk of severe disease or death. In October, a team from the University of Maryland School of Medicine found that hospitalised COVID-19 patients taking a daily dose of aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin. “This is a critical finding that needs to be confirmed through a randomised clinical trial,” said study leader Assistant Professor Jonathan Chow. “If our finding is confirmed, it would make aspirin the first widely available, over-the-counter medication to reduce mortality in COVID-19 patients.”
Another study revealed that osteoporosis treatments including denosumab, zoledronate and calcium may protect patients against COVID-19 and could result in a 30 to 40 percent reduction in the rate of infection. Most recently, researchers discovered that women taking metformin prior to hospitalisation had a significantly reduced risk of death from COVID-19 – read more about it here.
This year, we also saw innovation in the field of drug delivery, with a novel microneedle developed that successfully administered a COVID-19 vaccine to mice. The team, from the University of Pittsburgh School of Medicine, US, created a fingertip-sized patch that induces the production of antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralising the virus. Meanwhile, scientists from the University of Birmingham developed a nasal spray using compounds already approved by various regulatory bodies. Testing their drug delivery system in cell cultures, they say this could provide protection to patients against COVID-19.
In February, I spoke with Adrian van den Hoven, Director General of Medicines for Europe, to discover how drug shortages can impact patients and the pharmaceutical industry. He explained how to prevent and reduce the effects of medicinal scarcities in the EU: “We think it makes sense to encourage more companies to enter those markets so you have more manufacturers competing and supplying.” Mentioning the impact of Brexit, van den Hoven said that there are agreements in place to maintain the free flow of medicines between the EU and UK; however, with the deadline drawing ever closer, we will soon see whether this will mitigate any potential shortages.
In my cannabinoid series, I spoke with Dr Andy Yates from Artelo Bioscience to find out more about the company’s new cannabidiol (CBD) cocrystal and how it could be used to treat post-traumatic stress disorder (PTSD). I learnt that the CBD is formulated with tetramethylpyrazine (TMP) in a 1:1 ratio lattice, which can solubilise in aqueous media and break apart into the two component parts. Also in this series, I explored the process of growing and extracting active pharmaceutical ingredients (APIs) as well as a synthetic CBD tablet.
In August, US President Donald Trump announced the ‘Buy American’ executive order, with the aim of securing a more stable and secure drug supply chain for the country. I investigated what the executive order would mean for drug manufacturers in the US and globally – click here to read the article.
With the end of the year approaching, it is easy to pinpoint some of the landmark successes that the pharmaceutical and biopharmaceutical industries have achieved in 2020. Hopefully, next year will bring even more advancements that will improve the lives of patients worldwide.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.